ArticleESMO real world data and digital oncology2025
The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) visualisation: picturing the evidence of clinical benefit of clinical trial data.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Added benefits of systemic uro-oncological therapies-risk of recourse following elimination of the special practice designation : Part 1: prostate cancer].Urologie (Heidelberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Choosing the right cancer treatment is crucial for patients and health care professionals, while health care systems must allocate resources efficiently. The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) assists decision making by assessing the clinical benefit of anticancer medications. ESMO developed and field-tested a visualisation of the ESMO-MCBS scores to increase its user-friendliness and effectiveness. Methods: An expert panel iteratively designed and internally reviewed a prototype of the visualisation, then refined it through field-testing. A survey was conducted concurrently with the field-testing to evaluate the understandability of the visualisation. Field-testing materials and survey questions were made accessible to the public on the ESMO website and promoted at the ESMO Congress 2019 through ESMO social media platforms. The insights gathered from all the feedback were instrumental in refining the design. Subsequently, a conclusive survey was deployed during the ESMO Congress 2023 to assess the final version of the visualisation. Results: A two-panel visualisation was developed to reflect the steps of the ESMO-MCBS scoring procedure. Field-testing included visualisations for 121 studies, each based on their ESMO-MCBS scores. Feedback from the survey ( Conclusions: The visualisations offer a visual understanding of the ESMO-MCBS scores by enhancing user-friendliness and understandability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.